2. UroToday Home
  3. Video Lectures

PSMA Targeted Therapy

Lutetium-177 PSMA-617 Therapy Across the Prostate Cancer Spectrum: Mechanism, Formulation, and Future Directions - Phillip Koo
Phase 2 TheraPb Trial Evaluates a Novel Induction and Maintenance Regimen of 212Pb-ADVC001 Across Three Metastatic Prostate Cancer Indications - Anna Karmann
PSMACare: Early Lutetium RLT in High-Risk nmCRPC - Fred Saad
Implementing Lutetium-PSMA — From Trial Design to Operations - Oliver Sartor
Pluvicto™ Expands to Pre-Chemotherapy Space for PSMA-Positive Prostate Cancer - Steven Finkelstein
Lutetium-177 Outperforms Cabazitaxel in mCRPC: Real-World Flatiron Database Analysis - Zeynep Irem Ozay
Actinium-PSMA J591 After Prior Lutetium Therapy in Metastatic Prostate Cancer - Scott Tagawa
Combining Alpha and Beta Emitters in PSMA-Targeted Prostate Cancer Therapy - Scott Tagawa
Lutetium-177 PSMA Radioligand Therapy Advances to Earlier mCRPC Setting - Daniel Petrylak & Steven Finkelstein
Health-Related Quality Outcomes for Pre-Chemotherapy mCRPC Treatment - Neal Shore
First Patient Experience with Pre-Chemotherapy Pluvicto™ for mCRPC Treatment - James Wasielewski
First Patient Treated with Pluvicto™ in Pre-Chemotherapy Setting Following FDA Approval - Steven Finkelstein
FDA Approval of 177Lu-PSMA-617 for Taxane-Naive mCRPC - Oliver Sartor
Exploring Actinium-225 in PSMA-Targeted Therapy for Prostate Cancer - Michael Morris
ProstACT GLOBAL Trial: Combining PSMA-Targeted Therapy with ARPIs and Docetaxel - Oliver Sartor
Tumor Dosimetry in PSMA Therapy: A VISION Substudy Analysis - Ken Herrmann
Online Platform Maps Theranostic Trials Worldwide for Patients and Physicians - Luke Nordquist
Combining Lutetium-PSMA with Hormonal Therapy Enhances Prostate Cancer Treatment - Louise Emmett
ARROW Study Reveals Iodine-131 PSMA Efficacy in Advanced Cancer - Evan Yu
Novel Epigenomic Liquid Biopsy Detects PSMA Expression in Prostate Cancer - Jacob Berchuck
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann
Exploring Actinium-225: Transforming Cancer Treatment with Targeted Radiopharmaceuticals - John Valliant
Dose-Escalation of Lutetium PSMA: Final Results from a Phase I/II Trial - Scott Tagawa
Comparing PSMA Ligands for Prostate Cancer Imaging - Michael Hofman
Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations - Louise Emmett
Patient Selection for Radioligand Therapy: Case Study Discussion - Amir Iravani & Evan Yu
Operationalizing and Coordinating Lutetium-177 PSMA Treatment: Roles of a Multidisciplinary Prostate Cancer Team - Kristen Davis & Sarah Yenser Wood
Patient Selection for PSMA Radioligand Therapy - Ephraim Parent
Predictive Markers in Metastatic Prostate Cancer: Insights from the VISION Trial - Oliver Sartor
Radioligand Therapy's Role in Treating mCRPC - Oliver Sartor
Highlights: UCLA/UCSF Inaugural PSMA PET and RLT Conference - Jeremie Calais
ENZA-p Trial Explores Enzalutamide-Lutetium Combination in Prostate Cancer - Louise Emmett
LuTectomy Study Shows Promise: Targeted Radiation Safe Before Prostate Cancer Surgery - Michael Hofman & Renu Eapen
Tumor Heterogeneity Selective Pressure – Why We Need New Targets? - Oliver Sartor
PSMA PET as a Biomarker for Advanced Prostate Cancer - Oliver Sartor
The Evolution of PSMA Theranostics: A 30-Year Journey with the Prostate Cancer Foundation - Andrea Miyahira
PSMA PET and Radioligand Therapy: A Comprehensive Two-Day Conference by UCLA and UCSF - Jeremie Calais & Thomas Hope
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy - Thomas Hope
The Radiopharmaceutical Revolution: New Frontiers in Prostate Cancer Treatment - Oliver Sartor
From the VISION Trial: Improved Patient Outcomes with Lutetium-PSMA-617 - Karim Fizazi
PSMA-Targeted Radioligand Therapy and Liquid Biopsy Characterizing PSMA Expression in Men with Metastatic Castration-Resistant Prostate Cancer - Andrew Armstrong
Exploring the Potential of Lutetium PSMA in High-Risk Localized Prostate Cancer: The LuTectomy Trial - Renu Eapen
Exploring the Landscape of mCRPC: PARP Inhibitors, PSMA Radioligand Therapy, and More - Alicia Morgans
The Implementation of PSMA Theranostics in Clinical Practice - Oliver Sartor
A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices - Neal Shore
Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris
Pluvicto™ (177Lu-PSMA-617) Indications for Clinical Use in PSMA Positive Metastatic Castration-Resistant Prostate Cancer mCRPC - Oliver Sartor
Appropriate Use Criteria for PSMA PET Imaging - Hossein Jadvar
Ongoing Clinical Trials Evaluating The Efficacy of Targeted Radioligand Therapy - Shahneen Sandhu
The Use of Imaging for Patient Selection for PSMA Directed Therapies – Jeremie Calais
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris
Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor
The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris
Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu
Transforming The Standard of Care for Men With Advanced-Stage PSMA-Positive mCRPC, Published Results from the Phase III VISION Trial - Oliver Sartor
PSMAddition, the Integration of Lutetium-177 With the Standard of Care Therapy in Metastatic Castrate-Sensitive Prostate Cancer Patients – Scott Tagawa & Oliver Sartor
The VISION Trial Demonstrates 177Lu-PSMA-617 Significantly Improves Overall Survival and rPFS in mCRPC – Oliver Sartor
A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher Wallis & Zachary Klaassen
177 Lu-PSMA-617 Offers a Promising Treatment for Men with Progressing mCRPC. - Declan Murphy & Michael Hofman
Outcomes of Patients From PSMA Targeted Radionuclide Trials - Panagiotis Vlachostergios
Targeted Radionuclide Therapy of Prostate Cancer - Wolfgang Weber
TheraP: 177Lu-PSMA617 Theranostic vs Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) - Michael Hofman & Ian Davis
TheraP Trial Design Evaluating 177Lu‐PSMA‐617 Theranostic Treatment vs Cabazitaxel in Progressive Metastatic Castration‐Resistant Prostate Cancer - Michael Hofman
Targeted Molecular Therapies for Treatment of Advanced Prostate Cancer - Scott Tagawa
The Evolving Role of Lutetium-PSMA in the Era of Personalized Medicine - Michael Hofman
Early Initiation of Lu177 PSMA Radioligand Therapy Prolongs Survival in Metastatic PCa - Harshad Kulkarni
High Activity Pain Reduction and Low Toxicity with Lu177 PSMA617 Theranostics - Michael Hofman
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris
177LU-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer - Oliver Sartor
A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial, Interview with Oliver Sartor
PSMA Targeted Therapies Presentation - Michael Hofman
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman
Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617 - Jeremie Calais